Cannabics Pharmaceuticals
3 Bethesda Metro Center, #700
Bethesda
Maryland
20814
United States
Tel: 877-424-2429
Website: http://www.cannabics.com/
Email: info@cannabics.com
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals is dedicated to the development of Personalized Anti-Cancer treatments.YEAR FOUNDED:
2012
LEADERSHIP:
Founder and CEO: Itamar Borochov
FOLLOW CANNABICS:
Tweets by Cannabics
99 articles with Cannabics Pharmaceuticals
-
CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials
11/4/2021
Cannabics Pharmaceuticals Inc. announced today that it has signed an agreement with Purisys, a leading Active Pharmaceutical Iingredient (API) manufacturer, for supply of Good Manufacturing Practice (GMP) grade APIs required for the manufacturing of RCC-33, the company's colorectal cancer treatment drug candidate.
-
Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors
10/25/2021
Cannabics Pharmaceuticals Inc. announced today that Dr. Yonina Tova (MD), internationally recognized Radiation Oncologist has joined the company's Board of Advisors.
-
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
10/18/2021
Cannabics Pharmaceuticals Inc. announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.
-
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
9/21/2021
Cannabics Pharmaceuticals Inc . announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases.
-
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
9/13/2021
Cannabics Pharmaceuticals Inc. announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine.
-
Cannabics Pharmaceuticals Appoints a Second Independent Board Member
7/20/2021
Cannabics Pharmaceuticals Inc. announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director.
-
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
7/7/2021
Cannabics Pharmaceuticals Inc. announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director.
-
Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice
6/28/2021
Cannabics Pharmaceuticals Inc. released today the interim results of its second in-vivo POC study evaluating the efficacy of company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer on mice.
-
Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases
6/17/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.
-
Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
6/3/2021
Cannabics Pharmaceuticals Inc., a global leader in the development of cancer related cannabinoid-based medicine, announced the launching of a new research program for the development of a Breast Cancer antitumor targeting medicine.
-
The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology
5/25/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the company's patent titled: "System and Method for High Throughput Screening of Cancer Cells" has been granted by the European Patent Office .
-
Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations
5/11/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had filed a patent application under the Patent Cooperation Treaty (PCT) for novel formulations developed for treatment of various cancer types.
-
Cannabics Pharmaceuticals Receives Patent Notice of Allowance From The Mexican Patent and Trademark Office (IMPI)
5/6/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had received "Notice of Allowance" from the Mexican Patent and Trademark Office (IMPI) in relation to the company's patent titled: 'System and method for high throughout screening of cancer cells"
-
There are several experimental treatments undergoing study for types of melanoma. BioSpace rounds up some of the most recent clinical news in this space.
-
Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program
4/20/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program using Psylocibin and Psilocin.
-
Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33
3/31/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today it is initiating a Dose Response in-vivo Study in mice; results to be included as part of the Product Package to be submitted to the U.S. Food and Drug Administration
-
Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells
3/17/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice
-
Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016
2/17/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, further clarifies with regards to the final study results released on February 16, 2021 ,
-
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
2/16/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice.
-
Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
2/3/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cance